On the other hand, when combined with endocrine therapy, CDK4/6 inhibitor has become a first-line therapy as a combination drug with endocrine therapy for estrogen receptor (ER)-positive and HER2-negative breast cancer [9], and multiple clinical trials are exploring various combination treatments involving CDK4/6 inhibitors [10]. This evidence concerns the gene ESR1 and breast carcinoma.